Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 6:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,708 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Acute Chest Pain, NSTEMI - Non-ST Segment Elevation MI
Interventions
European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm, European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm
Diagnostic Test
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years and older
Enrollment
64,374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Myocardial Ischemia, Left Ventricular Systolic Dysfunction, Elevated Cardiac Enzymes
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Royal Oak, Michigan
Completed Not applicable Interventional Results available

Abbott Next Generation Drug Eluting Stent 48mm Study

NCT04282148
Conditions
Coronary Artery Disease
Interventions
ABT NG DES 48 EECSS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 13 more
Conditions
Acute Coronary Syndrome, Multi Vessel Coronary Artery Disease, Ischemic Stroke
Interventions
Life and Medication Recommendations
Behavioral
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Completed No phase listed Observational Results available

Extracellular Matrix Marker of Arrhythmia Risk (EMMA)

NCT00376532
Conditions
Myocardiopathies, Ischemia, Myocardial, Arrythmia, Death, Sudden, Cardiac
Interventions
Not listed
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Coronary Artery Disease
Interventions
ticagrelor, clopidogrel
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
San Diego, California
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

NCT01607450
Conditions
Type 2 Diabetes Mellitus, Healthy
Interventions
GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose, Saline
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Coronary Artery Disease
Interventions
RXi System, Pressure Wire
Device
Lead sponsor
Acist Medical Systems
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
La Jolla, California • Long Beach, California • Stanford, California + 8 more
Conditions
Coronary Artery Disease, Myocardial Ischemia, Bleeding
Interventions
clopidogrel 600 mg, arterial access sheath
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Diabetes Mellitus, Coronary Artery Disease, Heart Failure
Interventions
Ambio Health Remote Monitoring
Behavioral
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Myocardial Infarction
Interventions
TG100-115
Drug
Lead sponsor
TargeGen
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Transthyretin Amyloidosis With Cardiomyopathy
Interventions
Nucresiran, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
42
States / cities
La Jolla, California • Laguna Hills, California • Stanford, California + 35 more
Completed Phase 4 Interventional Results available

Kidney Damage in Patients With Normal eGFR

NCT01137786
Conditions
Coronary Artery Stenosis
Interventions
Non ionic contrast media comparator
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Springfield, Illinois
Terminated Phase 1Phase 2 Interventional Results available

Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

NCT01458405
Conditions
Myocardial Infarction
Interventions
CAP-1002 Allogeneic Cardiosphere-Derived Cells, Placebo
Biological · Drug
Lead sponsor
Capricor Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
32
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 27 more
Conditions
Diabetes Mellitus, Ischemic Heart Disease
Interventions
100 million Allogeneic Mesenchymal Human Stem Cells, Placebo
Drug · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Heart Failure
Interventions
Anakinra, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Terminated Phase 4 Interventional Results available

Effects of Atorvastatin on Myonecrosis

NCT00344019
Conditions
Coronary Disease
Interventions
Placebo Oral Tablet, Atorvastatin 80mg, Screening
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Lumbar Spinal Stenosis, Cardiac Amyloidosis, ATTR Amyloidosis Wild Type, ATTR Gene Mutation, ATTRV122I Amyloidosis, Cardiomyopathy, Hypertrophic
Interventions
Tc99-PYP or Tc99-HDMP Scan
Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
1,663 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
6
States / cities
Beverly Hills, California • Boston, Massachusetts • Rochester, Minnesota + 2 more
Terminated Not applicable Interventional Accepts healthy volunteers

The Impact of Early Follow-up on Readmission Rates in AMI Patients

NCT02276456
Conditions
Myocardial Infarction
Interventions
Follow-up Appointment- early vs standard
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Coronary Artery Disease
Interventions
Regadenoson
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Coronary Artery Disease
Interventions
Regadenoson (Lexiscan) [muti-detector computed tomography]
Device
Lead sponsor
Tennessee Heart and Vascular Institute, P.C.
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Hendersonville, Tennessee
Conditions
Cardiomyopathy, Heart Failure, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Coronary Artery Disease
Interventions
Same day discharge, Overnight Stay
Behavioral
Lead sponsor
Trinity Health Michigan
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Ypsilanti, Michigan